An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization
- Bipolar I Disorder
- Mania
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Neurocrine Biosciences
- Enrolment target
- 150
- Started
- 24 December 2025
- Main results due
- February 2028
- Study sites
- 11
- Registry updated
- 29 September 2026
Can you take part?
- Ages 18 years to 65 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of bipolar I disorder. * The participant has had at least 1 prior documented manic episode that required treatment. * The participant is experiencing an acute manic episode or manic episode with mixed features, with or without psychotic symptoms. Key Exclusion Criteria: * Any unstable or poorly controlled medical condition or chronic disease (including history of neurological, hepatic, renal, cardiovascular, gastrointestinal, pulmonary, autoimmune, or endocrine disease that may affect study participation or results), or malignancy within 90 days before the start of screening. * Primary diagnosis is not bipolar I disorder. * History of clozapine treatment for treatment-resistant psychosis. * History of psychiatric hospitalization(s) for ≥30 consecutive days during the 90 days before the start of screening. Note: Additional inclusion/exclusion criteria may apply, per protocol.
What this study is about
In the sponsor’s own words, from the registry.
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving manic symptoms in adults with bipolar I disorder who are currently experiencing an episode of mania with or without mixed features.
Study sites(11)
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Recruiting
Neurocrine Clinical Site
Cerritos, California, United States
Recruiting
Neurocrine Clinical Site
Garden Grove, California, United States
Recruiting
Neurocrine Clinical Site
San Diego, California, United States
Recruiting
Neurocrine Clinical Site
Hollywood, Florida, United States
Recruiting
Neurocrine Clinical Site
Atlanta, Georgia, United States
Recruiting
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Recruiting
Neurocrine Clinical Site
Marlton, New Jersey, United States
Recruiting
Neurocrine Clinical Site
Staten Island, New York, United States
Recruiting
Neurocrine Clinical Site
Austin, Texas, United States
Recruiting
Neurocrine Clinical Site
Houston, Texas, United States
Recruiting
Showing 11 of 11 sites. 11 of the 11 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07288320. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me